Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

2(50.0%)

N/A

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 3(2)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT01315652Not ApplicableCompleted

Interest of a Standardized Monitoring of Rheumatoid Arthritis: The COMEDRA Trial

Role: collaborator

NCT04888221Phase 3Active Not Recruiting

Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement

Role: collaborator

NCT04723693Completed

An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families

Role: collaborator

NCT04239196Phase 2Unknown

Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA

Role: collaborator

NCT02908217Phase 3Completed

Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

Role: collaborator

All 5 trials loaded